MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Large Decline in Short Interest

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) saw a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 360,500 shares, a decline of 35.8% from the May 15th total of 561,600 shares. Based on an average daily trading volume, of 236,400 shares, the short-interest ratio is presently 1.5 days. Approximately 1.6% of the shares of the stock are short sold.

MAIA Biotechnology Stock Performance

Shares of MAIA stock traded down $0.02 on Tuesday, hitting $1.70. 144,948 shares of the stock traded hands, compared to its average volume of 268,840. MAIA Biotechnology has a twelve month low of $1.40 and a twelve month high of $4.24. The firm’s 50-day moving average price is $1.82 and its two-hundred day moving average price is $2.02. The stock has a market capitalization of $44.47 million, a PE ratio of -1.23 and a beta of 0.20.

Insider Buying and Selling

In other MAIA Biotechnology news, Director Stan Smith bought 33,333 shares of MAIA Biotechnology stock in a transaction dated Tuesday, June 3rd. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $49,999.50. Following the completion of the transaction, the director now directly owns 1,305,059 shares of the company’s stock, valued at approximately $1,957,588.50. This represents a 2.62% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 36.98% of the stock is currently owned by insiders.

Institutional Trading of MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. Jane Street Group LLC acquired a new stake in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 39,057 shares of the company’s stock, valued at approximately $77,000. Jane Street Group LLC owned 0.15% of MAIA Biotechnology as of its most recent filing with the Securities and Exchange Commission. 5.65% of the stock is currently owned by institutional investors and hedge funds.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.